Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam delivered a record quarter with $1.036 billion in global net product revenues, up 121% year-over-year, marking the first time quarterly product sales exceeded $1 billion. The performance was fueled by AMVUTTRA and ONPATTRO, which together generated $910 million in TTR revenues, prompting the company to reiterate its full-year 2026 revenue guidance of $4.9 billion to $5.3 billion.
Key figures
- Eps
- 1.51
- Revenue
- $1,036 Million
- Guidance
- Combined Net Product Revenues of $4,900 Million to $5,300 Million
- Revenue Yoy
- 121%
- Total ttr revenues
- $910 Million
- Ttr revenue growth
- 153%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.